Compass Therapeutics, Inc.
CMPXDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Oct 23, 2026
4wMarket Overview
Stock performance and key metrics
1 upcoming, 0 past
How CMPX's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
CTX-009 | Phase 3 | Metastatic Colorectal Cancer | - | - |
Psilocybin | Phase 3 | Post Traumatic Stress Disorder | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Compass Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Compass Therapeutics, Inc.'s (CMPX) pipeline across Phase 3. Its lead program is CTX-009 (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Compass Therapeutics, Inc.'s next FDA catalyst?→
Compass Therapeutics, Inc.'s (CMPX) next tracked catalyst is a Conference expected October 23, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track CMPX biotech catalysts?→
Add CMPX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Compass Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.